Skip to main content
. 2022 Jun 9;108(1):171–180. doi: 10.3324/haematol.2021.280550

Figure 2.

Figure 2.

Outcome of the patients. (A) Progression free-survival (PFS) and (B) overall survival (OS) of the 160 patients with relapsed/refractory diffuse large B-cell lymphoma. (C) PFS according to Deauville score (DS) at 1 month (M1) evaluation (DS1-3 vs. DS-4 vs. DS-5). (D) OS according to DS at M1 evaluation (DS1-3 vs. DS-4 vs. DS-5). (E) PFS according to ΔSUVmax (70%) between positron emission tomography on day zero (PET0) and PETM1. (F) OS according to ΔSUVmax (70%) between PET0 and PETM1.